European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
EMA CHMP recommends label update to Novo Nordisk’s Wegovy
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s Wegovy label.
EMA committee recommends Novo Nordisk’s Wegovy label update to reflect reduced heart failure symptoms and improved physical function
Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST]
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms and improved physical function.
Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits
Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.
Medpage Today on MSN5mon
Wegovy Helps HFpEF Patients With Diabetes Mellitus
The findings mirrored those of the similarly designed STEP-HFpEF trial in a population without type 2 diabetes. A pooled ...
Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets
In its quarterly earnings presentation, Novo Nordisk said that in January 2024, it submitted the results from Wegovy STEP HFpEF trials for regulatory review in the US and EU. Based on interactions ...
The American Journal of Managed Care23d
Semaglutide Enhances Heart Failure Outcomes in Obesity
Semaglutide and Atrial Fibrillation A subanalysis of data from the STEP-HFpEF and STEP-HFpEF DM trials 5 showed that patients with aFib—45% of the STEP-HFpEF program population—have ...
Medscape9mon
Heart failure and transplantation with Dr Ileana Piña
ACC 2024 Semaglutide Benefits in HFpEF Step Beyond Weight Loss Drs Piña and Kosiborod discuss semaglutide in obesity-related HF with and without diabetes. Both STEP HFpEF trials show similar ...
PipelineReview.com1d
Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...
FiercePharma22d
Novo rekindles heart failure hopes for semaglutide with new pooled analysis
After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. Novo’s semaglutide cut the ...